Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Prognostic modeling in diffuse large B-cell lymphoma in the era of immunochemotherapy: Where do we go from here?

Literature DB >> 28464215

Prognostic modeling in diffuse large B-cell lymphoma in the era of immunochemotherapy: Where do we go from here?

Jean L Koff¹, Christopher R Flowers¹.

Abstract

Entities: Chemical Disease Gene Species

Mesh：

Year: 2017 PMID： 28464215 PMCID： PMC5738913 DOI： 10.1002/cncr.30740

Source DB: PubMed Journal: Cancer ISSN： 0008-543X Impact factor: 6.860

× No keyword cloud information.

17 in total

1. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.

Authors: P Feugier; A Van Hoof; C Sebban; P Solal-Celigny; R Bouabdallah; C Fermé; B Christian; E Lepage; H Tilly; F Morschhauser; P Gaulard; G Salles; A Bosly; C Gisselbrecht; F Reyes; B Coiffier
Journal: J Clin Oncol Date: 2005-05-02 Impact factor: 44.544

Review 2. The 2016 revision of the World Health Organization classification of lymphoid neoplasms.

Authors: Steven H Swerdlow; Elias Campo; Stefano A Pileri; Nancy Lee Harris; Harald Stein; Reiner Siebert; Ranjana Advani; Michele Ghielmini; Gilles A Salles; Andrew D Zelenetz; Elaine S Jaffe
Journal: Blood Date: 2016-03-15 Impact factor: 22.113

3. Cancer-specific mortality, cure fraction, and noncancer causes of death among diffuse large B-cell lymphoma patients in the immunochemotherapy era.

Authors: Nadia Howlader; Angela B Mariotto; Caroline Besson; Gita Suneja; Kim Robien; Naji Younes; Eric A Engels
Journal: Cancer Date: 2017-05-02 Impact factor: 6.860

4. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy.

Authors: Matthew J Maurer; Hervé Ghesquières; Jean-Philippe Jais; Thomas E Witzig; Corinne Haioun; Carrie A Thompson; Richard Delarue; Ivana N Micallef; Frédéric Peyrade; William R Macon; Thierry Jo Molina; Nicolas Ketterer; Sergei I Syrbu; Olivier Fitoussi; Paul J Kurtin; Cristine Allmer; Emmanuelle Nicolas-Virelizier; Susan L Slager; Thomas M Habermann; Brian K Link; Gilles Salles; Hervé Tilly; James R Cerhan
Journal: J Clin Oncol Date: 2014-02-18 Impact factor: 44.544

5. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.

Authors: Christine P Hans; Dennis D Weisenburger; Timothy C Greiner; Randy D Gascoyne; Jan Delabie; German Ott; H Konrad Müller-Hermelink; Elias Campo; Rita M Braziel; Elaine S Jaffe; Zenggang Pan; Pedro Farinha; Lynette M Smith; Brunangelo Falini; Alison H Banham; Andreas Rosenwald; Louis M Staudt; Joseph M Connors; James O Armitage; Wing C Chan
Journal: Blood Date: 2003-09-22 Impact factor: 22.113

6. Evaluating cell-of-origin subtype methods for predicting diffuse large B-cell lymphoma survival: a meta-analysis of gene expression profiling and immunohistochemistry algorithms.

Authors: Jay A Read; Jean L Koff; Loretta J Nastoupil; Jessica N Williams; Jonathon B Cohen; Christopher R Flowers
Journal: Clin Lymphoma Myeloma Leuk Date: 2014-06-12

7. 2016 US lymphoid malignancy statistics by World Health Organization subtypes.

Authors: Lauren R Teras; Carol E DeSantis; James R Cerhan; Lindsay M Morton; Ahmedin Jemal; Christopher R Flowers
Journal: CA Cancer J Clin Date: 2016-09-12 Impact factor: 508.702

8. Population-specific prognostic models are needed to stratify outcomes for African-Americans with diffuse large B-cell lymphoma.

Authors: Qiushi Chen; Turgay Ayer; Loretta J Nastoupil; Jean L Koff; Ashley D Staton; Jagpreet Chhatwal; Christopher R Flowers
Journal: Leuk Lymphoma Date: 2015-12-15

9. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis.

Authors: Adam M Petrich; Mitul Gandhi; Borko Jovanovic; Jorge J Castillo; Saurabh Rajguru; David T Yang; Khushboo A Shah; Jeremy D Whyman; Frederick Lansigan; Francisco J Hernandez-Ilizaliturri; Lisa X Lee; Stefan K Barta; Shruthi Melinamani; Reem Karmali; Camille Adeimy; Scott Smith; Neil Dalal; Chadi Nabhan; David Peace; Julie Vose; Andrew M Evens; Namrata Shah; Timothy S Fenske; Andrew D Zelenetz; Daniel J Landsburg; Christina Howlett; Anthony Mato; Michael Jaglal; Julio C Chavez; Judy P Tsai; Nishitha Reddy; Shaoying Li; Caitlin Handler; Christopher R Flowers; Jonathon B Cohen; Kristie A Blum; Kevin Song; Haowei Linda Sun; Oliver Press; Ryan Cassaday; Jesse Jaso; L Jeffrey Medeiros; Aliyah R Sohani; Jeremy S Abramson
Journal: Blood Date: 2014-08-26 Impact factor: 22.113

10. Randomized Phase 2 Open-Label Study of R-CHOP ± Bortezomib in Patients (Pts) With Untreated Non-Germinal Center B-Cell-like (Non-GCB) Subtype Diffuse Large Cell Lymphoma (DLBCL): Results From the Pyramid Trial (NCT00931918).

Authors:
Journal: Clin Adv Hematol Oncol Date: 2016-02

5 in total

4. To Determine the Prognostic Significance of 18-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Scan-Derived Parameters (Total Lesion Glycolysis and Metabolic Tumor Volume) in Patients of Diffuse Large B-Cell Lymphoma with Only Nodal Involvement.

Authors: Nitin Gupta; Natasha Singh
Journal: Indian J Nucl Med Date: 2020-03-12

5. Predictive value of baseline ¹⁸F-FDG PET/CT and interim treatment response for the prognosis of patients with diffuse large B-cell lymphoma receiving R-CHOP chemotherapy.

Authors: Lili Zhu; Yankai Meng; Lili Guo; Hanqing Zhao; Yue Shi; Shaodong Li; Anming Wang; Xiaojun Zhang; Jing Shi; Jie Zhu; Kai Xu
Journal: Oncol Lett Date: 2020-12-18 Impact factor: 2.967